YolTech Therapeutics key facts
as of Oct 2026- Developer of in vivo gene editing therapies focusing on serious diseases using lipid nanoparticle delivery systems.
- YolTech Therapeutics is valued at approximately $135.8M as of Oct 2026 (last reported valuation).
- It has raised $75.1M; the latest was Early Stage VC ($45.0M) in Sep 2025.
- Notable investors include Green Pine Capital Partners, K2VC, Unity Ventures (China), Tianjin Venture Capital, Anhui Guokong Capital — 14 tracked in total.
- Status: Privately Held (backing).
YolTech Therapeutics's last reported valuation, Sep 2023. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch YolTech Therapeutics: the Monday email on marks, rounds and moves
YolTech Therapeutics funding rounds
No funding rounds for YolTech Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs YolTech Therapeutics
14+Membership and data by Private Market View
YolTech Therapeutics valuation
YolTech Therapeutics's last reported valuation was $136 million in Sep 2023. No priced round, secondary trade or fund mark has surfaced since.
YolTech Therapeutics investors
14 investors are on record for YolTech Therapeutics, including Green Pine Capital Partners, K2VC, Unity Ventures (China) and Tianjin Venture Capital.
About YolTech Therapeutics
Developer of in vivo gene editing therapies focusing on serious diseases using lipid nanoparticle delivery systems. The company specailises in clinical-stage therapies targeting transthyretin amyloidosis, familial hypercholesterolemia and primary hyperoxaluria type 1, thereby improving treatment outcomes through scalable, high-quality manufacturing and next-generation gene editing technologies.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- yoltx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.